
Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) – Research analysts at HC Wainwright cut their FY2027 EPS estimates for shares of Century Therapeutics in a note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.48) per share for the year, down from their previous forecast of ($0.47). The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.51) per share.
IPSC has been the topic of a number of other research reports. Weiss Ratings downgraded Century Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Wall Street Zen upgraded Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $4.75.
Read Our Latest Report on Century Therapeutics
Century Therapeutics Trading Down 0.6%
Century Therapeutics stock opened at $1.64 on Tuesday. The firm has a market cap of $296.95 million, a P/E ratio of -2.56 and a beta of 1.78. Century Therapeutics has a 1-year low of $0.43 and a 1-year high of $3.04. The firm has a 50-day moving average of $1.64 and a 200-day moving average of $2.06.
Century Therapeutics (NASDAQ:IPSC – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in IPSC. Commodore Capital LP purchased a new position in shares of Century Therapeutics in the 1st quarter valued at approximately $19,652,000. BlackRock Inc. purchased a new stake in Century Therapeutics in the second quarter worth $19,825,000. Seven Fleet Capital Management LP purchased a new stake in Century Therapeutics in the first quarter worth $9,826,000. Trails Edge Capital Partners LP bought a new position in Century Therapeutics in the second quarter worth $10,130,674. Finally, Spruce Street Capital LP purchased a new position in Century Therapeutics during the second quarter valued at $9,944,682. Hedge funds and other institutional investors own 50.20% of the company’s stock.
Century Therapeutics Company Profile
Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.
Recommended Stories
- Five stocks we like better than Century Therapeutics
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
